Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (8727)	5/30/1998 5:40:00 PM
From: Zebra 365	Respond to of 23519

Here is the old press release on ICOS. Zebra ICOS Announces Initiation of Overseas Phase 2 Trial With IC351 BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 13, 1998--ICOS Corporation (NASDAQ:ICOS - news) announced today the initiation of a Phase 2 clinical trial with IC351 in patients with male erectile dysfunction (MED). This randomized placebo-controlled, crossover study is being performed overseas. The Phase 2 clinical trial includes patients with mild to moderate MED. The study is designed to assess the safety and physiological effects of IC351 in this patient population. Approximately 20-30 million men in the United States are estimated to suffer from some degree of MED. This condition, sometimes referred to as impotence, can be a consequence of several factors, among them cardiovascular insufficiency. IC351 is a selective PDE5 phosphodiesterase inhibitor that is thought to reinforce the normal physiological signals to increase blood flow. Such an increase in blood flow is an integral part of the erectile response. The Company's goal is to demonstrate that IC351 is a useful treatment for MED and cardiovascular disorders. ICOS is discovering and developing new pharmaceuticals by seeking points of intervention in the inflammatory process that may lead to specific and efficacious drugs. ICOS' research and drug development programs involve both acute and chronic conditions such as ARDS, acute pancreatitis, asthma, hemorrhagic shock, male erectile dysfunction, multiple sclerosis, myocardial infarction, and psoriasis.

To: VLAD who wrote (8727)	5/30/1998 5:40:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

Perry, The article is from the Motley Fool and I will transcribe the part I was refering to: The magazine hyped the drug as "the son of Viagra" and quoted Jim McCamant, editor of a medical technology newsletter in Berkeley, CA, as saying ICOS IC351 drug "will be a potentially better product...because it has fewer side effects." This was news to the company itself, which has finished one small Phase 2 trial, is continuing a bigger Phase 2 trial of IC351, and has yet to release any clinical data on the drug. In other words Perry, all this hoopla over ICOS was based on one remark by a guy who just said something without any facts to support his statement. Even the company itself said it was news to them.